Online inquiry

IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12247MR)

This product GTTS-WQ12247MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12247MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7211MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ5236MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ1035MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ10443MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ3379MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ15041MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ3166MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ8991MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMA-638
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW